George Yancopoulos, Regeneron president and CSO (Brendan McDermid/Reuters/Alamy)
August 3, 2022 12:13 PM EDT
Bioregnum
Pharma

George Yan­copou­los says he's on the trail of the holy grail: ‘This could rep­re­sent the next break­through for im­munother­a­py’

Two of the most out­spo­ken — and suc­cess­ful — drug de­vel­op­ers in biotech say they’ve col­lect­ed ear­ly-stage clin­i­cal da­ta that are point­ing them down the trail to …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times